Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Pulmonary function tests in pseudoexfoliation syndrome

Poster Details

First Author: M. Batur TURKEY

Co Author(s):    E. Seven                    

Abstract Details

Purpose:

It is well known that pseudoexfoliative material deteriorates iris dilatation function. This material also was found in lung tissue. The aim of the study is to evaluate pulmonary functions in cases with pseudoexfoliation.

Setting:

Yuzuncu Yil University, Medical Faculty Department of Ophthalmology

Methods:

In this prospective study, 60 pseudoexfoliation syndrome without any pulmonary diseases and 52 age and gender matched controls without any pulmonary diseases were investigated. Tobacco use and systemic diseases such as diabetes mellitus, arterial hypertension, asthma were asked in all cases. All cases underwent full ophthalmologic, general medical examinations including pulmonary osculation and pulmonary PA X-ray. Pulmonary function tests were used for evaluation of pulmonary functions. FVC, FEV%, FEV1, FEV1/FVC and saturation values were recorded.

Results:

Mean age was 67.1±8.8 years in pseudoexfoliation group and 63.8± 9.4 years in control group (p>0.05). Mean FEV1 were 1.60±0.62 in pseudoexfoliation group and 1.84±0.61 in control group (p=0.036). Mean FEV% were 70.65±23.89 in pseudoexfoliation group and 83.46±17.83 in control group (p=0.002). Mean FEV1/FVC also were 0.72±0.15 in pseudoexfoliation group and 0.77±0.11 in control group (p=0.043). No statistically significant difference were found for FVC, saturation and smoking between the groups.

Conclusions:

These result suggest that some pulmonary functions decrease in pseudoexfoliation syndrome.

Financial Disclosure:

NONE

Back to Poster listing